Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Employees

Sector

Biotechnology & Medical Research

Calendar

26/02 - Q2 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
15/01/26	0.008000 $	-5.88%	218,189
14/01/26	0.008500 $	0.00%	95,560
13/01/26	0.008500 $	+6.25%	2,665,442
12/01/26	0.008000 $	0.00%	391,993
09/01/26	0.008000 $	0.00%	924,847

Delayed Quote Australian S.E., 15 January 2026 at 03:26 pm AEDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.008500AUD

Average target price

0.0385AUD

Spread / Average Target

+352.94%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Australian S.E. Other stock markets 03:26:48 15/01/26 pm AEDT			5-day change	1st Jan Change
0.008000 ^AUD	-5.88%		0.00%	-

17/12	Canaccord Genuity Starts Alterity Therapeutics at Speculative Buy with AU$1.60 Price Target	MT
21/11	Alterity Therapeutics Chairman Retires	MT

Capitalization	61.8M 53.03M 49.38M 45.95M 85.75M 5.58B 92.44M 568M 223M 2.67B 232M 227M 9.78B	P/E ratio 2026 *	-0.09x	P/E ratio 2027 *	-0.17x
Enterprise value	7.44M 6.38M 5.94M 5.53M 10.32M 672M 11.13M 68.35M 26.89M 321M 27.9M 27.33M 1.18B	EV / Sales 2026 *	-	EV / Sales 2027 *	16.2x
Free-Float	96.36%	Yield 2026 *	-	Yield 2027 *	-

17/12	Canaccord Genuity Starts Alterity Therapeutics at Speculative Buy with AU$1.60 Price Target	MT
21/11	Alterity Therapeutics Chairman Retires	MT
21/11	Alterity Therapeutics says Julian Barbaczy appointed non-exec chair	RE
21/11	Alterity Therapeutics Limited Announces Board Changes, Effective 21 November 2025	CI
10/11	Alterity Therapeutics Presents Promising Impact of Ath434 on Orthostatic Hypotension and Disease Progression in Msa At the 36Th International Symposium on the Autonomic Nervous System	CI
10/11	Alterity Therapeutics Says ATH434 Drug Candidate Efficacy in Multiple System Atrophy Impacted by Baseline Disease Characteristics	MT
10/10/25	Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial At the 2025 International Congress of Parkinson's Disease and Movement Disorders	CI
09/10/25	Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study	MT
02/10/25	Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders	CI
15/09/25	Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting	CI
08/09/25	Alterity Therapeutics raises A$20.0 million in strategic placement	RE
08/09/25	Alterity Therapeutics Raises AU$20 million Via Placement	MT
08/09/25	Alterity Therapeutics Ltd raises A$20 million in capital	RE

17/12	Canaccord Genuity Starts Alterity Therapeutics at Speculative Buy with AU$1.60 Price Target	MT
09/10/25	Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study	MT
02/10/25	Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders	CI
03/02/25	Benchmark Downgrades Alterity Therapeutics to Hold From Speculative Buy	MT
03/08/22	Ladenburg Thalmann Initiates Alterity Therapeutics at Buy With $2 Price Target	MT

Alterity Therapeutics Limited Stock

Equities

ATH

AU0000043945

Biotechnology & Medical Research

Valuation: Alterity Therapeutics Limited

Chart: Alterity Therapeutics Limited

Latest news: Alterity Therapeutics Limited

Last Transcript: Alterity Therapeutics Limited

Analysts' recommendations: Alterity Therapeutics Limited

Press Releases: Alterity Therapeutics Limited

Quotes and Performance

Course Extremes

Managers and Directors: Alterity Therapeutics Limited

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

10/11	Alterity Therapeutics : Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System	PU
03/11	Alterity Therapeutics : Appendix 4C – Q1 FY26 Quarterly Cash Flow Report	PU
09/10/25	Alterity Therapeutics : Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders	PU
02/10/25	Alterity Therapeutics : to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders	PU
15/09/25	Alterity Therapeutics : Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting	PU

1 week	0.01	0.01
1 month	0.01	0.01
Current year	0.01	0.01
1 year	0.01	0.02
3 years	0	0.02
5 years	0	0.05
10 years	0	0.41

Manager	Title	Age	Since
David Stamler CEO	Chief Executive Officer	65	07/01/2021
Abby Niven DFI	Director of Finance/CFO	-	30/09/2024

Director	Title	Age	Since
Peter Marks BRD	Director/Board Member	70	29/07/2005
Lawrence Gozlan BRD	Director/Board Member	47	08/08/2011
David Stamler BRD	Director/Board Member	65	21/11/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ALTERITY THERAPEUTICS LIMITED	-5.88%	0.00%	-15.79%	-27.27%	61.8M
LONZA GROUP AG	+0.75%	+2.14%	+3.60%	+12.27%	49.05B
IQVIA HOLDINGS INC.	-0.09%	-1.20%	+21.92%	+8.65%	41.1B
BEONE MEDICINES AG	-1.23%	+3.86%	+72.52%	+28.11%	38.37B
CELLTRION, INC.	-4.30%	+0.24%	+19.22%	+36.66%	31.59B
REVOLUTION MEDICINES, INC.	+1.06%	+18.02%	+204.34%	+302.86%	23.43B
MEDPACE HOLDINGS, INC.	+1.32%	+0.55%	+86.29%	+169.71%	17.36B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+8.08%	-33.49%	+27,398.05%	+4,371.14%	17.39B
EUROFINS SCIENTIFIC SE	-0.22%	+4.21%	+54.86%	+10.57%	14.83B
ICON PUBLIC LIMITED COMPANY	+0.81%	-8.94%	-7.73%	-17.69%	14.11B
Average	+0.02%	-2.16%	+2,783.73%	+489.50%	24.73B
Weighted average by Cap.	+0.19%	-0.25%	+1,973.06%	+360.54%

	2026 *	2027 *
Net sales	-	1.65M 1.42M 1.32M 1.23M 2.29M 149M 2.47M 15.18M 5.97M 71.35M 6.2M 6.07M 261M
Net income	-12.99M -11.14M -10.38M -9.66M -18.02M -1.17B -19.42M -119M -46.93M -561M -48.71M -47.7M -2.06B	-13.94M -11.96M -11.13M -10.36M -19.33M -1.26B -20.84M -128M -50.36M -602M -52.26M -51.19M -2.21B
Net Debt	-54.36M -46.65M -43.43M -40.42M -75.43M -4.91B -81.31M -499M -196M -2.35B -204M -200M -8.6B	-34.98M -30.02M -27.95M -26.01M -48.54M -3.16B -52.33M -321M -126M -1.51B -131M -129M -5.54B

1 day	-5.88%
3 months	-36.00%
6 months	-33.33%